Criteria
| Eligible Active Ingredient: | Olopatadine. As an eyedrop not exceeding 0.2% |
| With Effective From: | 1-Dec-16 |
| Indication Permitted: | Short-term treatment of symptoms of allergic conjunctivitis |
| Maximum Daily Dose: | 0.2%: One drop in each affected eye once a day |
| Maximum Supply per Transaction: | 0.2%: 2.5ml |
| Minimum Age of User: | 3 years |
| Patient Information Leaflet from HSA/PSS: | Download PIL (Link to HSA website) |
Mechanism of Action of Olopatadine
Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.
Additional Information of Olopatadine
| Pharmacology Class: | Decongestants And Antiallergics |
| Therapeutic Class: | Ophthalmologicals |
| Chemical Class: | Other Antiallergics |
| Synonyms: | Olopatadin | Olopatadina | Olopatadine | Olopatadinum | Opatanol |
Show All HSA-registered therapeutic products granted exemption to supply without prescription
References
HSA-Registered Products Containing Olopatadine As an eyedrop not exceeding 0.2%
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.